Shopko Optical 075 | |
2510 S Reserve St, Missoula, MT 59801-7546 | |
(406) 721-4646 | |
Not Available |
Full Name | Shopko Optical 075 |
---|---|
Type | Facility |
Speciality | Eyewear Supplier |
Location | 2510 S Reserve St, Missoula, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174576748 | NPI | - | NPPES |
0550862 | Medicaid | MT | |
17878 | Other | MEDICARE | |
35494 | Other | AVESIS | |
213121-21 | Other | EYEMED | |
014075 | Other | VIP |
Mailing Address | Practice Location Address |
---|---|
Shopko Optical 075 2510 S Reserve St, Missoula, MT 59801-7546 Ph: (406) 721-4646 | Shopko Optical 075 2510 S Reserve St, Missoula, MT 59801-7546 Ph: (406) 721-4646 |
News Archive
Researchers at the Hebrew University of Jerusalem have succeeded in discovering and isolating a new protein from the poplar tree with special structural and qualitative characteristics that could have consequences for development of future nanocapsules for drug delivery to cancer cells.
Osaka Researchers, in partnership with other Japanese and U.S. scientists, report a new gene target, KPNB1, for treatment against epithelial ovarian cancer (EOC).
When the COVID-19 pandemic arrived in North America in March 2020, health care facilities stopped providing all but "essential" care, to reduce infection risks and preserve protective gear known as PPE.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
› Verified 1 days ago